Gennadii Grabovyi

Gennadii Grabovyi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
LRLaura Riva
Laura Riva
AWAshley K. Woods
Ashley K. Woods
GGGennadii Grabovyi
Gennadii Grabovyi
ACArnab K. Chatterjee
Arnab K. Chatterjee
There remains a need to develop novel SARS-CoV-2 therapeutic options that improve upon existing therapies by an increased robustness of response, fewer safety liabilities, and global-ready accessibility. Functionally critical viral main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target due to its homology within the coronaviral family, and lack thereof toward human proteases. In this disclosure, we outline the advent of a novel SARS-CoV-2 3CLpro inhibitor, CMX990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. Compared with the marketed drug nirmatrelvir (combination with ritonavir = Paxlovid), CMX990 has distinctly differentiated potency (∼5× more potent in primary cells) and human in vitro clearance (>4× better microsomal clearance and >10× better hepatocyte clearance), with good in vitro-to-in vivo correlation. Based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, CMX990 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.

20 September 2016 in Organic Letters
Verified
Journal Article
Closed access
GGGennadii Grabovyi
Gennadii Grabovyi
JMJustin T. Mohr
Justin T. Mohr

21 May 2020 in Organic Letters
Verified
Journal Article
Closed access
GGGennadii Grabovyi
Gennadii Grabovyi
ABAisha Bhatti
Aisha Bhatti
JMJustin T. Mohr
Justin T. Mohr

23 July 2018 in Synthesis
Verified
Journal Article
Closed access
PDF file
BSBrian M. Stoltz
Brian M. Stoltz
CDChristian Defieber
Christian Defieber
JMJustin T. Mohr
Justin T. Mohr
GGGennadii Grabovyi
Gennadii Grabovyi
A short enantioselective formal synthesis of the antibiotic natural product platencin is reported. Key steps in the synthesis include enantioselective decarboxylation alkylation, aldehyde/olefin radical cyclization, and regioselective aldol cyclization.

20 March 2017 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
NLNikolay Lukashev
Nikolay Lukashev
GGGennadii Grabovyi
Gennadii Grabovyi
DEDmitry A Erzunov
Dmitry A Erzunov
AKAlexey V. Kazantsev
Alexey V. Kazantsev
GLGennadij V. Latyshev
Gennadij V. Latyshev
Irina Petrovna  BeletskayaIrina Petrovna Beletskaya
Irina Petrovna Beletskaya
Cu- and Pd-catalyzed arylation of aminocholanes has been described for the first time. While this Cu-catalyzed protocol provides high yields in reactions of aminocholanes with iodoarenes, Pd catalysis was found to be preferable for the reactions of aminocholanes with dichloroanthraquinones. UV–vis titration of bis(cholanylamino)anthraquinones with a series of cations demonstrated their high binding affinity to Cu2+, Al3+, and Cr3+.

21 November 2024 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
CRCatherine C. Rouch
Catherine C. Rouch
ACArnab K. Chatterjee
Arnab K. Chatterjee
CMConnor McCarty
Connor McCarty
LSLirui Song
Lirui Song
ACAlan Chu
Alan Chu
GGGennadii Grabovyi
Gennadii Grabovyi
The papain-like protease (PLpro) is a highly conserved domain encoded by the coronavirus (CoV) genome and it plays an essential role in the replication and maturation of the virus in addition to weakening host immune response. Due to the virus's reliance on PLpro for survival and propagation, small-molecule inhibitors of PLpro serve as an attractive model for direct-acting antiviral therapeutic agents against SARS-CoV-2. Building upon existing work aimed at designing covalent inhibitors against PLpro, we report the synthesis and structure-activity relationship of analogs based on the known covalent inhibitor 1 (Sanders, et al.2023). To evaluate the efficacy of synthesized derivatives, we conducted enzymatic inhibition assays, SARS-CoV-2/HeLa-ACE2 cellular potency and toxicity assays, and profiled the most promising analogs via in vitro ADME and in vivo pharmacokinetic studies. Additionally, we describe computational docking of profiled compounds bound to PLpro to elucidate the structure-activity relationship of compounds based on 1 and offer suggestions for optimizing the potency and selectivity of the electrophilic warhead and improving ADME and PK properties for this chemotype. Relative to the parent compound, new designs demonstrate comparable potency and target selectivity for PLpro. The accomplished SAR campaign provides novel insight for future development of antivirals against SARS-CoV-2.